XAIR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
XAIR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Beyond Air's Earnings per Share (Diluted) for the three months ended in Dec. 2024 was $-0.15. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.06.
Beyond Air's EPS (Basic) for the three months ended in Dec. 2024 was $-0.15. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.06.
Beyond Air's EPS without NRI for the three months ended in Dec. 2024 was $-0.13. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.04.
During the past 3 years, the average EPS without NRIGrowth Rate was -14.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was -28.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 10 years, Beyond Air's highest 3-Year average EPS without NRI Growth Rate was 18.80% per year. The lowest was -52.20% per year. And the median was -7.60% per year.
The historical data trend for Beyond Air's EPS (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beyond Air Annual Data | |||||||||||||||||||||
Trend | Jun15 | Jun16 | Dec17 | Mar18 | Mar19 | Mar20 | Mar21 | Mar22 | Mar23 | Mar24 | |||||||||||
EPS (Diluted) | Get a 7-Day Free Trial |
![]() |
![]() |
-1.78 | -1.27 | -1.68 | -1.86 | -1.82 |
Beyond Air Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
EPS (Diluted) | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-0.50 | -0.36 | -0.27 | -0.28 | -0.15 |
For the Medical Devices subindustry, Beyond Air's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Beyond Air's PE Ratio distribution charts can be found below:
* The bar in red indicates where Beyond Air's PE Ratio falls into.
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
Beyond Air's Diluted EPS for the fiscal year that ended in Mar. 2024 is calculated as
Diluted EPS (A: Mar. 2024 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (-60.242 | - | 0) | / | 33.160 | |
= | -1.82 |
Beyond Air's Diluted EPS for the quarter that ended in Dec. 2024 is calculated as
Diluted EPS (Q: Dec. 2024 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (-13.032 | - | 0) | / | 88.075 | |
= | -0.15 |
EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.06
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beyond Air (NAS:XAIR) EPS (Diluted) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Beyond Air's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Robert Carey | director | HORIZON PHARMA, INC., 520 LAKE COOK ROAD, SUITE 520, DEERFIELD IL 60062 |
Michael A. Gaul | officer: Chief Operating Officer | 425 MARTINGALE ROAD, SUITE 1000, SCHAUMBURG IL 60173-2213 |
Steven A. Lisi | director | 2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635 |
Erick Lucera | director | 138 THISTLE ROAD, NORTH ANDOVER MA 08145 |
Amir Avniel | director, officer: President & CEO | 2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635 |
Jeff Lynn Myers | officer: Chief Medical Officer | C/O BEYOND AIR, INC., 900 STEWART AVENUE, SUITE 301, GARDEN CITY NY 11530 |
William P Forbes | director | C/O SALIX PHARMACEUTICALS, LTD., 8510 COLONNADE CENTER DRIVE, RALEIGH NC 27615 |
Yoori Lee | director | C/O AIT THERAPEUTICS, INC., 500 MAMARONECK AVENUE, HARRISON NY 10528 |
Ron Bentsur | director | 750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022 |
Douglas Quinton Larson | officer: Chief Financial Officer | BEYOND AIR, INC., 900 STEWART AVENUE, SUITE 301, GARDEN CITY NY 11530 |
Douglas Beck | officer: Chief Financial Officer | C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711 |
Ari Raved | director | 2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635 |
Jerome B Zeldis | director | 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258 |
David Grossman | director | 2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635 |
Haim Aviv | officer: Chief Financial Officer | 2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635 |
From GuruFocus
By GuruFocus News • 11-12-2024
By Marketwired • 02-10-2025
By Marketwired • 08-06-2024
By Marketwired • 10-02-2024
By Marketwired • 07-23-2024
By Marketwired • 12-02-2024
By Marketwired • 03-11-2025
By Marketwired • 11-14-2024
By Marketwired • 09-23-2024
By GuruFocus News • 02-15-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.